Breast Cancer News and Research

Latest Breast Cancer News and Research

Institute of Medicine to be congratulated for calling more resources to fight hypertension

The Institute of Medicine is to be congratulated for sounding the call for more resources to fight hypertension (high blood pressure), the number two preventable cause of death and a leading contributor to heart disease and stroke. Heart disease and stroke are the number one and three overall causes of death of individuals in the United States.

25 Feb 2010

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

TWC, TSC announce the grand opening of new facilities at St. John’s Medical Plaza in Santa Monica

Tower Wound Care Center of Santa Monica and Tower Surgical Center are pleased to announce the grand opening of its new state-of-the-art facilities at St. John’s Medical Plaza in Santa Monica, California.

25 Feb 2010

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.

24 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

USPSTF-recommended guidelines lead to decline in mammograms and early detection programs for women under 50

In some states women ages 40 to 49 have less access to mammograms since the U.S. Preventive Services Task Force (USPSTF) released its recommendations to change breast cancer screening guidelines last November, according to a recent survey conducted by the Avon Foundation for Women. The USPSTF recommended changing the current mammography screening guidelines for average risk women to begin biennial screening at age 50 instead of annual mammograms starting at age 40.

24 Feb 2010

Scientists identify key mechanism of drug resistance in breast cancer patients

CANCER RESEARCH UK funded scientists have discovered why some breast cancers are resistant to the commonly used drug tamoxifen, their findings are published in Cancer Research.

24 Feb 2010

Findings suggest bitter melon extract may help in preventing breast cancer

Bitter melon extract, a common dietary supplement, exerts a significant effect against breast cancer cell growth and may eventually become a chemopreventive agent against this form of cancer, according to results of a recent study.

23 Feb 2010

Menssana Research develops 85% accurate breath test for pulmonary tuberculosis

A new breath test can detect active pulmonary tuberculosis, according to a report to be published in the journal "Tuberculosis."

23 Feb 2010

USPSTF mammography recommendations: Avon Foundation for Women survey confirms states denying coverage

A recent Avon Foundation for Women survey confirms what the American College of Radiology and other experts warned would happen: states are using deeply flawed and widely discredited U.S. Preventative Services Task Force mammography recommendations to deny women coverage for mammograms, and many women are foregoing long proven, life-saving mammography care based on the mistaken USPSTF recommendations.

23 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

Combining PARP inhibitors with existing cancer drugs promising

Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports.

23 Feb 2010

Unique resource for families facing hereditary breast and ovarian cancer

When she was forty-two, Joi Morris learned that she has a genetic mutation on a gene known as BRCA2. This meant that her risk of getting breast cancer could be as high as 84 percent by age seventy, and that her risk for ovarian cancer was also high.

23 Feb 2010

Combination of MRI and mammography reduces mortality rate in high-risk women

Annual breast cancer screening with both mammography and magnetic resonance imaging (MRI) is likely to be a cost-effective way to improve life expectancy in women with an increased risk of breast cancer, according to a new study published in the March issue of Radiology.

23 Feb 2010

Ritter Pharmaceuticals to discuss lactose intolerance and associated health risks at NIH Conference

Ritter Pharmaceuticals, a company dedicated to helping individuals live a healthier and happier life style through improved digestion, announced today that it will join the leading lactose intolerance experts around the country at the NIH Consensus Development Conference for Lactose Intolerance and Health in Bethesda, Maryland from February 22-24.

22 Feb 2010

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.

22 Feb 2010

RNCRR uses Parascript' AccuDetect CAD software to detect breast cancer

Parascript, LLC, the image analysis and pattern recognition solution provider, today announced the use of its AccuDetect computer aided detection (CAD) software by the Russian Center for Roentgeno - Radiology Research in Moscow. RNCRR is Russia's largest, most recognized breast cancer oncology center.

22 Feb 2010

Greater New York City Affiliate of Susan G. Komen for the Cure commences one-year celebration of its 20th anniversary

The Greater New York City Affiliate of Susan G. Komen for the Cure® is kicking off a one-year celebration of its 20th anniversary with the publication of its first-ever eight-page full-color newsletter looking back on the past 20 years, recapping 2009 and gazing into the organization’s future.

22 Feb 2010

Researchers develop new tool to understand how cancer grows

Researchers have a new tool to understand how cancers grow -- and with it a new opportunity to identify novel cancer drugs. They've been able to break apart human prostate tissue, extract the stem cells in that tissue, and alter those cells genetically so that they spur cancer.

22 Feb 2010

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia™ (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.

20 Feb 2010

Breast Cancer News and Research

Latest Breast Cancer News and Research

Institute of Medicine to be congratulated for calling more resources to fight hypertension

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

TWC, TSC announce the grand opening of new facilities at St. John’s Medical Plaza in Santa Monica

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

USPSTF-recommended guidelines lead to decline in mammograms and early detection programs for women under 50

Scientists identify key mechanism of drug resistance in breast cancer patients

Findings suggest bitter melon extract may help in preventing breast cancer

Menssana Research develops 85% accurate breath test for pulmonary tuberculosis

USPSTF mammography recommendations: Avon Foundation for Women survey confirms states denying coverage

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Combining PARP inhibitors with existing cancer drugs promising

Unique resource for families facing hereditary breast and ovarian cancer

Combination of MRI and mammography reduces mortality rate in high-risk women

Ritter Pharmaceuticals to discuss lactose intolerance and associated health risks at NIH Conference

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

RNCRR uses Parascript' AccuDetect CAD software to detect breast cancer

Greater New York City Affiliate of Susan G. Komen for the Cure commences one-year celebration of its 20th anniversary

Researchers develop new tool to understand how cancer grows

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Breast Cancer News and Research

Latest Breast Cancer News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in